Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of LX-039 in ER+/HER2- Advanced Breast Cancer
NCT04097756Phase 1Completed
- Sponsor
- Shandong Luoxin Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LX-039 in breast cancer (2 arms), sponsored by Shandong Luoxin Pharmaceutical. Primary endpoint: Tolerance of LX-039 (DLT) at 4 weeks. Started Jan 2020; status: completed.
02
Drugs
LX-039
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04097756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097756.